The market for anti-aging and longevity drugs for companion dogs is an emerging and rapidly growing sector within veterinary medicine. Research into extending the healthy lifespan of pets has gained significant momentum, driven by advances in geroscience and increasing pet owner investment in animal health.
According to a 2024 market analysis report by Research and Markets, the global veterinary anti-aging market, which includes diagnostics, therapeutics, and supplements, was valued at approximately $2.1 billion in 2023. The firm projects it could reach $5.34 billion by 2035, growing at a compound annual growth rate (CAGR) of 8.5%.
Several biotech companies are actively developing pharmaceutical interventions. Notably, Loyal, a veterinary biotech company, announced in late 2025 that it had completed a major study for its drug LOY-001, aimed at extending the lifespan of large dogs, and had submitted data to the FDA's Center for Veterinary Medicine. Other entities, like the Dog Aging Project, continue large-scale research into the biological mechanisms of aging in dogs.
While the field shows promise, experts emphasize that most potential therapies are still in clinical investigation. The path to regulatory approval is rigorous, focusing on both safety and demonstrated health benefits for aging dogs, rather than simply extending lifespan.
